VA tests smart tool to boost liver cancer screening in veterans

NCT ID NCT06061328

First seen Jan 05, 2026 · Last updated Jun 19, 2026 · Updated 25 times

Summary

This study tests a new decision aid tool that helps VA medical centers pick the best strategies to improve liver cancer screening for veterans with cirrhosis. About 8,020 veterans and clinicians will take part across multiple VA sites. The goal is to see if the tool leads to more patients getting the recommended screening and better health outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA

    Pittsburgh, Pennsylvania, 15240, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

decision aid training (behavioral intervention)

What this could lead to

If successful, this could provide a simple, data-driven tool to help hospitals choose the best strategies for improving care, leading to better liver cancer screening rates.

What could go wrong

This is a behavioral study, not a drug trial. The tool may not improve screening rates more than current methods, and results may not apply outside the VA system.

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis hepatocellular carcinoma Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.